1. Bill of Materials without prices.docx

The document is a Bill of Materials listing two key items: 96 doses of PYLARIFY (piflufolastat F 18) Injection and 8 unused dose fees. This bill of materials is associated with a Notice of Intent (NOI-CC-26-000012) by the National Institutes of Health Clinical Center (NIH-CC) to sole-source procure radiopharmaceuticals from Progenics Pharmaceuticals Inc. The procurement is specifically for compounded piflufolastat F-18 in patient-ready unit doses, to be supplied by Sofie Nuclear Pharmacy for use in nuclear medicine diagnostics and treatments. The justification for sole-source procurement stems from the product being owned by Lantheus Medical/Progenics Pharmaceuticals, with Sofie Co. authorized to manufacture and distribute the radioactive drug, which has critical time-sensitivity due to rapid radiation decay and requires specialized handling by Nuclear Medicine personnel.